AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00022087 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: cholecalciferol
Description: 400 IU PO per day
Study NCT00553722 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eplerenone
Description: Administer Eplerenone, 25 mg,orally twice daily for 4 weeks.
Study NCT00553722 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administer a placebo tablet orally twice daily for 4 weeks.
Study NCT01346995 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental knee pain
Description: Injection of 1 ml hypertonic saline (5.8%) into the infrapatellar fat pad
Study NCT01346995 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-painful control injections
Description: Injection of isotonic saline into the infrapatellar fat pad
Study NCT01634191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast
Description: One oral 30 mg dose of apremilast
Study NCT01510457 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Milnacipran
Description: Total target dose of 200 mg/day. Subjects will titrate-up according to the following schedule: 25 mg/d (2 pills, 2 days), 50mg mg/d (4 pills, 2 days), 100mg/d (2 pills, 3 days), 150 mg/d (3 pills, 4 days), and steady state is reached once the study participant ingests 200 mg/d(4 pills). The steady state is maintained for 44 days (approx. 6 weeks). If intolerable side effects occur, the dose may be reduced to last tolerable does, a minimum of 100 mg/day at the discretion of the PI. Subjects unable to tolerate 100 mg/day will be discontinued from the study. A 2-week down-titration will be used.
Study NCT01510457 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive identical placebo pills and dosing schedule as that of participants receiving active study medication.
Study NCT00022087 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zoledronic acid
Description: 4 mg IV infusion q 3 months, months 1-24 in Zoledronic acid initial tx arm and months 13-36 in calcium + vit D initial tx arm
Study NCT01064167 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tranexamic Acid
Description: In tranexamic acid group, tranexamic acid, 1 g, was given 20 minutes before incision and 400 mg/h during the entire surgical procedure. The patients from control group were infused with normal saline as a placebo.
Study NCT01064167 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: In tranexamic acid group, tranexamic acid, 1 g, was given 20 minutes before incision and 400 mg/h during the entire surgical procedure. The patients from control group were infused with normal saline as a placebo.
Study NCT02397850 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: phone calls 30 min
Description: Patients receive either seven 30 minutes phone calls over 6 months (psychotherapy/continuation treatment)
Study NCT02397850 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: phone calls 50 min
Description: Patients receive either seven 50 minutes phone calls over 6 months (psychotherapy/continuation treatment)
Study NCT03964233 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ezabenlimab
Description: Solution for infusion
Study NCT03964233 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 754111
Description: Solution for infusion
Study NCT02489604 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-DOTATATE 25.9 GBq activity
Description: 177Lu-DOTATATE will be administered in a 30 minutes infusion. Total activity of 25.9 GBq 100 mCi for 7 cycles every 6 ± 2 weeks (700 mCi)
Study NCT02489604 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-DOTATATE 18.5 GBq activity
Description: 177Lu-DOTATATE will be administered in a 30 minutes infusion Total activity of 18.5 GBq 100 mCi for 5 cycles , every 6 ± 2 weeks (500 mCi)
Study NCT01314950 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home based occupational therapy
Description: An occupational therapist (OT) will deliver the home-based intervention. There are three cycles of intervention over two years, with each cycle delivering eight 60-90 minute home sessions. Cycle one takes place over 16 weeks, cycle two over 32 weeks, and cycle three over one year. Telephone calls take place in intervening weeks, with additional phone calls allowed to assist with problem solving and interval problems. At minimum, the OT will perform an assessment at the beginning of each cycle in order to tailor the home based component for individual dyads at each cycle. The OT will collaborate with the patients and caregivers to develop client centered goals with homework each week in order to encourage carryover of strategies, home environmental modifications, or home exercise programs.
Study NCT01314950 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Best practices primary care
Description: Collaborative care is provided by an advanced practice nurse working in collaborations with a family caregiver, the primary care physician, and geriatric medicine specialists. Caregivers complete a formal assessment of problematic behaviors to assess current symptoms and stressors, and the care manager makes recommendations based on these results and using standardized protocols. Protocols focus first on non-pharmacologic interventions. If these interventions fail, the care manager collaborates with the primary care physician and/or specialists to institute protocol-based drug therapy or other strategies. Patients and caregivers are also offered access to support groups.
Study NCT02029287 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hospital-Community-Family-Care Management Platform Online
Description: Hospital-Community-Family-Care Management Platform Online: the remote monitoring service platform on line based on community and family for subjects with CHF under the guidance of the regional central hospital
Study NCT02029287 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Subjects with CHF via conventional clinic visit according to the latest relevant guidelines
Description: Subjects with CHF via conventional clinic visit according to the latest relevant guidelines
Study NCT02029287 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Subjects with CHF via conventional clinic visit according to the latest relevant guidelines
Description: Subjects with CHF via conventional clinic visit according to the latest relevant guidelines
Study NCT03295864 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Multifrequency tympanometry at Inclusion
Description: Multifrequency tympanometry measurement and particularly width of conductance tympanograms at 2 kHz will be performed for both group at inclusion
Study NCT03295864 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Multifrequency tympanometry 6 month after surgery
Description: Multifrequency tympanometry measurement and particularly width of conductance tympanograms at 2 kHz will be performed 6 months after surgery for Chiari type I malformation patient
Study NCT04475614 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: BioGaia Prodentis lozenges
Description: oral probiotics
Study NCT04475614 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: low level laser treatment with Ga-Al-As laser
Description: low level laser treatment
Study NCT04475614 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: B vitamin injections (Neurobion, Merck, Darmstadt, Germany)
Description: intra muscular vitamin injections
Study NCT03776006 — intervention group
Intervention type: PROCEDURE
Intervention: Transperineal Laser Ablation
Description: Transperineal Laser Ablation of the Prostate
Study NCT02171975 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pre-procedure ultrasound guided paramedian spinal
Description: In group P, a portable ultrasound unit was used for initial pre-procedural marking. The interspinous space at which the clearest image of the anterior complex (ligamentum flavum dura complex- LFD) and posterior complex (posterior longitudinal ligament- PLL) was obtained, was selected. At the selected interspace, and with the probe positioned to obtain the clearest ultrasound image, a skin marker was used to mark the midpoint of the long border of the probe and the midpoints of the short borders of the probe . At the same horizontal level as the midpoint of the long border of the probe, the midpoint of the line drawn between the two short border midpoints of the probe was used as paramedian insertion point for the spinal needle.
Study NCT02171975 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional landmark guided midline spinal anaesthetic
Description: Spinal anaesthesia was administered based on conventional landmark based midline approach.
Study NCT03450083 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Benralizumab
Description: 30mg Benralizumab will be delivered subcutaneously
Study NCT03450083 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous placebo injection
Study NCT03608917 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Total Glucosides of Paeony(TGP)
Description: Total Glucosides of Paeony(TGP) as a traditional Chinese medicine, peony root is the dried root of peony of Ranunculaceae, cultivated all over the country.TGP is new drug of western medicine, original discovered by Professor Xu who is a famous pharmacologist. The main ingredient is a group of glycosides, including paeoniflorin, hydroxy paeoniflorin, paeoniflorin, paeoniflorin, benzoyl paeoniflorin etc, collectively referred to as total glucosides of paeony（TGP）
Study NCT03608917 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Narrow band-ultraviolet b（NB-UVB）
Description: phototherapy on treating vitiligo
Study NCT03608917 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Narrow band-ultraviolet b（NB-UVB）
Description: phototherapy on treating vitiligo
Study NCT03608917 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Total Glucosides of Paeony(TGP) analogue
Description: Total Glucosides of Paeony(TGP) analogue as a placebo for Control group
Study NCT02292771 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retosiban
Description: Solution for infusion, consisting of a clear colorless solution of retosiban at a concentration of 15 milligram/milliliter (mg/mL) in 56% volume/volume ethanol/acetate buffer concentrate supplied in 5 mL vial containing 75mg retosiban.
Study NCT02292771 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atosiban
Description: Clear, colorless solution for injection in a 0.9-mL vial containing 6.75 mg of atosiban. Clear, colorless concentrate for solution for infusion in a 5-mL vial containing 37.5 mg atosiban.
Study NCT02292771 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo matching retosiban
Description: A placebo infusion containing 0.9% sodium chloride (NaCl) matched for retosiban loading (bolus) dose and continuous infusion.
Study NCT02292771 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching atosiban
Description: A placebo infusion containing 0.9% NaCl matched for the atosiban loading (bolus) dose and continuous infusion.
Study NCT03895125 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: [year1] dual-task training with task priority strategy
Description: postural focus: focus mainly on postural performances while dual-tasking suprapostural focus: focus mainly on suprapostural performances while dual-tasking
Study NCT03895125 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: [year1] dual-task training with task priority strategy
Description: postural focus: focus mainly on postural performances while dual-tasking suprapostural focus: focus mainly on suprapostural performances while dual-tasking
Study NCT03895125 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: [year2-3] dual-task training with internal and external focus
Description: internal focus: focus mainly on body movements external focus: focus mainly on object in the environment
Study NCT01595815 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Calcium ionophore
Description: Oocytes were activated with calcium ionophore after ICSI
Study NCT01595815 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Strontium chloride (SrCl2)
Description: Oocytes were activated with strontium chloride after ICSI
Study NCT02532855 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: Sitagliptin 100 mg oral tablet
Study NCT02532855 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin
Description: Dapagliflozin 5 mg or 10 mg oral capsule. Up-titration to dapagliflozin 10 mg daily may be delayed if participant is unable to tolerate up-titration in the opinion of the investigator. Dapagliflozin 10 mg daily may be down-titrated to dapagliflozin 5 mg daily if participant is unable to tolerate the higher dose in the opinion of the investigator.
Study NCT02532855 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: This medication is a standard-of-care medication and is administered in an open-label fashion. Supply of background metformin oral tablet(s) (at least 1500 mg daily) will be the responsibility of the participant throughout the duration of the study.
Study NCT02532855 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: This medication is a standard-of-care medication and is administered in an open-label fashion. Supply of background metformin oral tablet(s) (at least 1500 mg daily) will be the responsibility of the participant throughout the duration of the study.
Study NCT02532855 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Matching placebo to sitagliptin
Description: Matching placebo to sitagliptin 100 mg oral tablet
Study NCT02532855 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching placebo to dapagliflozin
Description: Matching placebo to dapagliflozin 5 mg or 10 mg oral capsule. Up-titration to matching placebo to dapagliflozin 10 mg daily may be delayed if participant is unable to tolerate up-titration in the opinion of the investigator. Matching placebo to dapagliflozin 10 mg daily may be down-titrated to matching placebo to dapagliflozin 5 mg daily if participant is unable to tolerate the higher dose in the opinion of the investigator.
Study NCT02532855 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulfonylurea
Description: This medication is a standard-of-care medication and is administered in an open-label fashion. The dose of the sulfonylurea agent will be required to be at least 50% of maximum labeled dose, consistent with near maximum efficacy of the sulfonylurea agent.
Study NCT02532855 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfonylurea
Description: This medication is a standard-of-care medication and is administered in an open-label fashion. The dose of the sulfonylurea agent will be required to be at least 50% of maximum labeled dose, consistent with near maximum efficacy of the sulfonylurea agent.
Study NCT02421237 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Narrative Enhancement and Cognitive Therapy
Study NCT02421237 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supportive Group Therapy
Study NCT01769092 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fish Oil
Description: The daily dose is divided; capsules are taken with meals for a period of 6 months.
Study NCT01769092 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Safflower Oil
Description: Daily dose of safflower oil taken in divided doses as capsules and consumed with meals.
Study NCT01310335 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: whole-body vibration (WBV)
Description: All cases will be trained on a whole-body vibration (WBV) platform (Power Plate) 5 times a week for one week period.
Study NCT04166279 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Single rehabilitative treatment
Description: The rehabilitation treatment, performed by a physiotherapist trained in oncological rehabilitation, was carried out with a 6-week exercise program for 12 sessions (60 minutes/session, 2/week).). The protocol included a first phase consist in low impact aerobics warming (15-20 minutes), then diaphragmatic breathing and postural exercises for the midline alignment. The awareness of abdominal breathing represents the preliminary phase for a complete psychophysical relaxation of the patient, an important prerequisite for the correct execution of subsequent mobility, stretching and strengthening exercises of spine, scapula and upper limb. Subsequently, isometric strengthening exercises for shoulder stabilizing muscles, first passively and, subsequently, with supervision, were performed. Specific exercises, for passive mobilization and stabilization of the scapula, cervical pumping and stretching of the pectoral muscles, have been performed.
Study NCT04166279 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group rehabilitative treatment
Description: Four-five patients for group. The rehabilitation treatment, performed by a physiotherapist trained in oncological rehabilitation, was carried out with a 6-week exercise program for 12 sessions (60 minutes/session, 2/week). The protocol included at first week mainly breathing techniques, then we introduced exercises gradually more active, according to the improvements of the execution. The exercises had the aim to improve the opening of the scapular chain and to increase the amplitude of the range of motion in order to stimulate better neuromuscular control during the movement of scapular retropulsion, to stretch the pectoral muscles following the rhythm of the breath and the tissues affected by post-surgical scars and fibrotic effects, finally to reinforcing, against gravity, the musculature of the shoulders and back.
Study NCT03522441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clindamycin 1% Gel
Description: Topical gel
Study NCT03522441 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clindamycin 1% Gel
Description: Topical gel
Study NCT03522441 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Topical Placebo gel
Study NCT02642926 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Monopolar current
Description: Hysteroscopic surgical treatment of menorrhagia by use of monopolar current
Study NCT02642926 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bipolar current
Description: Hysteroscopic surgical treatment of menorrhagia by use of bipolar current
Study NCT03032952 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Feel Stress Free mobile application
Description: This online and mobile application uses relaxation techniques, thought challenging, mini-games and mood tracking to help reduce feelings of stress, anxiety and depression.
Study NCT00782548 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: KADIAN (morphine sulfate sustained-release) capsules
Description: Capsules, 30 mg
Study NCT00782548 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Avinza (morphine sulfate sustained-release) capsules
Description: Capsules, 30 mg
Study NCT00820573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: tablet, 100 mg/day, 6 weeks
Study NCT00820573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: tablet, 1000 mg/ bid, 6 weeks
Study NCT00820573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin + Metformin
Description: tablet, Sitagliptin (100mg/day) + tablet, Metformin (1000 mg/bid), 6 weeks
Study NCT00820573 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 6 weeks
Study NCT02388373 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone 250/formoterol 10
Study NCT02388373 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone 250/salmeterol 25
Study NCT02388373 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone 125/formoterol 5
Study NCT03978559 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: caspofungin
Description: caspofungin 70mg ivdrip the first day, then 50mg ivdrip qd for 21days
Study NCT03978559 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMP/SMZ(trimethoprim/sulfisoxazole)
Description: TMP:15mg/kg/d for 21 days +SMZ:75mg/kg/d for 21days
Study NCT03978559 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TMP/SMZ(trimethoprim/sulfisoxazole)
Description: TMP:15mg/kg/d for 21 days +SMZ:75mg/kg/d for 21days
Study NCT03978559 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: 40mg ivdrip q12h for 5 days , then 40mg ivdrip qd for 5 days , 20mg for 11 days
Study NCT03978559 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone
Description: 40mg ivdrip q12h for 5 days , then 40mg ivdrip qd for 5 days , 20mg for 11 days
Study NCT02456688 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imrecoxib
Study NCT04534777 — intervention group
Intervention type: OTHER
Intervention: repeated neurological, behavioral assessments and conventional, quantitative and functional brain imagery
Description: Based on the collected data, we will evaluate the respective diagnostic accuracy of all the markers acquired in clinical practice regarding the clinical outcome at 2 years.
Study NCT02471716 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FPA008
Description: FPA008 will be administered by IV infusion over approximately 30 minutes every 2 or 4 weeks